Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
|Articles|August 3, 2022
What To Do in San Diego
Author(s)Manny Garcia, MD
The president of the San Diego Psychiatric Society gives us a glimpse into the city for the upcoming 2022 Annual Psychiatric Times World CME Conference.
Advertisement
In this Mental Health Minute video, Manny Garcia, MD, of the San Diego Psychiatric Society makes some recommendations for sites to see and activities to enjoy while you are in San Diego, California, for the upcoming 2022 Annual Psychiatric Times™ World CME Conference.
Dr Garcia is president of the San Diego Psychiatric Society.
The
Advertisement
Related to this article
Therapeutic drug monitoring takes guesswork out of antipsychotic care —spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The First Ever Treatment-Resistant Depression Awareness Day
2
How Best to Manage Treatment-Resistant Depression
3
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
4
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
5